Replies to post #206028 on Biotech Values

[WorstLuck]

(including the CEO's exercise-and-hold transaction: #msg-124809319) was a harbinger of a higher share price.

Just for the sake of showing an example to the contrary - PVCT insiders have never sold, and have completed numerous exercise-and-hold transactions as well as participation in share offerings. Including some that were months to years ahead of the final exercise date.

Offhand I can't tell you how often the stock was significantly higher within a given time frame, but I can say that the judgment involved in those purchases from an investment standpoint have so far been nothing short of horrendous if one only considers stock price.

[biocqr]

CRBP > Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

https://www.thestreet.com/story/13892652/1/corbus-pharma-bear-thesis-is-alive-and-well-on-sclerosis-drug-data-skewed-positive.html

Why shouldn't these results be trusted? Because the sclerosis patients who received resunab were healthier at the start of the trial compared to the patients treated with placebo, Corbus' own data show.

The imbalances in patient baseline characteristics provided an assist to the resunab treatment response and undermines the credibility of the trial results, my investor source said.

After 12 weeks of treatment in the study, the FVC of resunab patients improved by approximately 0.85 percentage points. The FVC of the placebo patients declined by 0.75 percentage points. The FVC difference of 1.6 percentage points favored resunab, but again was smaller than the 6.4 percentage point difference at the start of the trial. It's also interesting to note -- and concerning -- that FVC in the resunab arm started to move sharply lower after patients were transitioned to the higher dose of the drug during the trial. By week 16, resunab patients were also showing decreased FVC compared to baseline.